Genitourinary/Renal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(CCTG) BL.13A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder CancerLalani, Dr Aly-KhanOpen to recruitmentNCT03768570
(CCTG) IND.234 / PC-BETS - Master ProtocolProstate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening ProtocolMukherjee, Dr SomOpen to recruitmentNCT03385655 (Master)
(CCTG) IND.234B/PC-BETS Sub-Study BA Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(B)
(CCTG) IND.234C/PC-BETS Sub-Study CA Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(C)
(CCTG) IND.234D/PC-BETS Sub-Study DA Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Mukherjee, Dr SomOpen to recruitmentNCT03385655(D)
(CCTG) IND.234E/PC-BETS Sub-Study EA Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA)Mukherjee, Dr SomOpen to recruitmentNCT03385655(E)
(CCTG) IND.234F/PC-BETS Sub-Study FA Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT03385655 (F)
(CCTG) IND.234G/PC-BETS Sub-Study GA Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT03385655 (G)
(CCTG) PR.20A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON)Quan, Dr KimmenOpen to recruitmentNCT03784755
(CHUM) 20.208 / PATRONPSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate CancerTsakiridis, Dr TheosOpen to recruitmentNCT04557501
(EXELIXIS) XL184-315 / CONTACT-02A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL 184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy(NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer.Hotte, Dr SebastienOpen to recruitmentNCT04446117
(Immunomedics) TROPICS-04 / IMMU-132-13A RANDOMIZED OPEN-LABEL PHASE III STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN SUBJECTS WITH METASTATIC OR LOCALLY ADVANCED UNRESECTABLE UROTHELIAL CANCERMukherjee, Dr SomOpen to recruitmentNCT04527991
(JCC) The PBS StudyA randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa)Tsakiridis, Dr TheosOpen to recruitmentNCT03380806
(Merck) MK-6482-012A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Lalani, Dr Aly-KhanOpen to recruitmentNCT04736706
(OHRI) RADIANT/OTT-19-07/OZM-105Neoadjuvant Immune-Modulating Radiation with Durvalumab (MEDI 4736) prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT)Lalani, Dr Aly-KhanOpen to recruitmentNCT04543110
(Seattle Genetics) SGN22E-003 / EV-302An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus
chemotherapy alone in previously untreated locally advanced
or metastatic urothelial cancer
Hotte, Dr SebastienOpen to recruitmentNCT04223856
(SHSC) AQuOS-IIAssessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II StudySwaminath, Dr AnandOpen to recruitmentNCT05023265
(UHN) WI222910 / ALPACAA Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based ChemotherapyMukherjee, Dr SomOpen to recruitmentNCT03391479
OCOG-2019-CYTOSHRINK / CA209-7DRCytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerLalani, Dr Aly-KhanOpen to recruitmentNCT04090710
(ESSA Pharma) EPI-7386-CS-010A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate CancerHotte, Dr SebastienSuspended/On holdNCT05075577
(JGH) PCS IX / PCS 9The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.Tsakiridis, Dr TheosSuspended/On holdNCT02685397
(Merck) MK-6482-011 / LiteSpark011An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 TherapyLalani, Dr Aly-KhanSuspended/On holdNCT04586231
Download PDF